Follow us on Twitter
twitter icon@FreshPatents


Erythropoietin patents

      

This page is updated frequently with new Erythropoietin-related patent applications.




 Tetrameric cytokines with improved biological activity patent thumbnailTetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
Ibc Pharmaceuticals, Inc.


 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications patent thumbnailErythropoietin and fibronectin compositions for therapeutic and cosmetic applications
A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject.
Remedor Biomed Ltd.


 Novel nitrogen-containing heteroaryl compounds and methods of use thereof patent thumbnailNovel nitrogen-containing heteroaryl compounds and methods of use thereof
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .
Fibrogen, Inc.


 Compounds that bind to the erythropoietin receptor patent thumbnailCompounds that bind to the erythropoietin receptor
The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin..
Epodose Llc


 New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases patent thumbnailNew compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases
Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds..

 Anti-erythropoietin antibodies patent thumbnailAnti-erythropoietin antibodies
The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies..
Amgen Inc.


 Method for purifying pegylated erythropoietin patent thumbnailMethod for purifying pegylated erythropoietin
Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange sp sephacryl™ s 500 hr chromatography material conditioned to a conductivity of 21 ms/cm and a linear gradient elution a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield..
Hoffmann-la Roche Inc.


 Use of paricalcitol in the treatment of inflammatory anaemia patent thumbnailUse of paricalcitol in the treatment of inflammatory anaemia
The present invention discloses the use of paricalcitol, a synthetic vitamin d analogue, in the treatment of inflammatory anaemia, preferably in combination with erythropoeisis-stimulating agents. The use of paricalcitol in the treatment of said pathology is associated with a reduced requirement for erythropoeisis-stimulating agents, with optimised iron absorption and with an increase in plasma erythropoietin levels in said patients.

 Purification of erythropoietin patent thumbnailPurification of erythropoietin
In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mm calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite..
F. Hoffmann-la Roche Ag


 Vectors conditionally expressing protein patent thumbnailVectors conditionally expressing protein
This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.
Intrexon Corporation


Conjugate comprising erythropoietin and a branched polymer structure

The present invention discloses a conjugate comprising erythropoietin (epo) and an asymmetric branched polymeric structure comprising two branches of monomethoxypolyethylene glycol (mpeg), where the molecular mass of one of these mpeg branches is between 10 kda and 14 kda, and the molecular mass of the other branch of mpeg is between 17 kda and 23 kda, as well as the pharmaceutical compositions containing it. The invention also provides a method for the preparation of pegylated epo, wherein said protein is conjugated to an asymmetric branched polymeric structure with two branches of mpeg having the above described molecular masses..
Centro De Inmunologia Molecular

Pharmaceutical composition comprising erythropoietin and ceftriaxone and a treating parkinson's disease dementia

The invention discloses a pharmaceutical composition for treating parkinson's disease dementia (pdd), which including erythropoietin and ceftriaxone. The invention also discloses a use of the pharmaceutical composition in the manufacture of a medicament for the treatment of pdd..
Raygene Biotech International Inc.

Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides

The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (epo)-derived oligopeptides.. .

Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients

The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (esa) comprising administering soluble ferric triphosphate (sfp) composition and administering a dose of esa that is significantly reduced compared to the dose of esa required by a dialysis patient that is hyporesponsive to esa that has not received sfp.. .
Rockwell Medical, Inc.

Tissue protective peptides and uses thereof

The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.

Isolated renal cells and uses thereof

The invention is directed to isolated renal cells, including tubular and erythropoietin (epo)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.. .
Regenmedtx, Llc

Compositions and methods for increasing erythropoietin (epo) production

The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting one or more egln genes, egln1, egln2 and/or egln3 and methods of using such dsrna compositions to inhibit expression of these genes.. .

Recombinant protein

A recombinant protein is provided. The recombinant protein of the invention comprises an erythropoietin and a highly glycosylated peptide, and has a longer half-life.

Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent

Wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin..

Derivatisation of erythropoietin (epo)

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited

Derivatisation of erythropoietin (epo)

The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of prostatic acid phosphatase, lactotransferrin, soluble erythropoietin receptor, von willebrand factor, soluble endothelial protein c receptor, and beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.

Compounds and methods for enhancing erythropoiesis

Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (i) indicated below, in which r is a glucosyl group.



Erythropoietin topics:
  • Erythropoietin
  • Red Blood Cell
  • Recombinant
  • Nucleic Acid
  • Genetically
  • Regulatory Sequence
  • Endogenous
  • Peptide Sequence
  • Carbamylated
  • Ischemic Stroke
  • Therapeutical
  • Intracranial
  • Thrombopoietin
  • Leukemia Inhibitory Factor
  • Somatostatin


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Erythropoietin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Erythropoietin with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.1429

    file did exist - 2558

    2 - 1 - 51